PL2124879T3 - Procesy wytwarzania implantów z lipidów cyklicznych do stosowania wewnątrzgałkowego - Google Patents

Procesy wytwarzania implantów z lipidów cyklicznych do stosowania wewnątrzgałkowego

Info

Publication number
PL2124879T3
PL2124879T3 PL07855073T PL07855073T PL2124879T3 PL 2124879 T3 PL2124879 T3 PL 2124879T3 PL 07855073 T PL07855073 T PL 07855073T PL 07855073 T PL07855073 T PL 07855073T PL 2124879 T3 PL2124879 T3 PL 2124879T3
Authority
PL
Poland
Prior art keywords
processes
cyclic lipid
intraocular use
making cyclic
implants
Prior art date
Application number
PL07855073T
Other languages
English (en)
Inventor
Lon T. Spada
James N. Chang
Michelle Luu
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of PL2124879T3 publication Critical patent/PL2124879T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
PL07855073T 2006-12-19 2007-12-12 Procesy wytwarzania implantów z lipidów cyklicznych do stosowania wewnątrzgałkowego PL2124879T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/612,928 US8846073B2 (en) 2006-12-19 2006-12-19 Low temperature processes for making cyclic lipid implants for intraocular use

Publications (1)

Publication Number Publication Date
PL2124879T3 true PL2124879T3 (pl) 2017-01-31

Family

ID=39467138

Family Applications (3)

Application Number Title Priority Date Filing Date
PL17198020T PL3308769T3 (pl) 2006-12-19 2007-12-12 Sposoby wytwarzania implantów z lipidem cyklicznym do zastosowania wewnątrzgałkowego
PL13179876T PL2712610T3 (pl) 2006-12-19 2007-12-12 Sposoby wytwarzania implantów wewnątrzgałkowych zawierających lipidy cykliczne
PL07855073T PL2124879T3 (pl) 2006-12-19 2007-12-12 Procesy wytwarzania implantów z lipidów cyklicznych do stosowania wewnątrzgałkowego

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL17198020T PL3308769T3 (pl) 2006-12-19 2007-12-12 Sposoby wytwarzania implantów z lipidem cyklicznym do zastosowania wewnątrzgałkowego
PL13179876T PL2712610T3 (pl) 2006-12-19 2007-12-12 Sposoby wytwarzania implantów wewnątrzgałkowych zawierających lipidy cykliczne

Country Status (11)

Country Link
US (5) US8846073B2 (pl)
EP (3) EP2124879B1 (pl)
JP (2) JP5484911B2 (pl)
AU (1) AU2007337139B2 (pl)
CA (1) CA2673294C (pl)
DK (3) DK3308769T3 (pl)
ES (3) ES2588187T3 (pl)
HK (1) HK1253728A1 (pl)
HU (3) HUE030404T2 (pl)
PL (3) PL3308769T3 (pl)
WO (1) WO2008079674A2 (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
IL177762A0 (en) * 2006-08-29 2006-12-31 Arieh Gutman Bimatoprost crystalline form i
ATE539102T1 (de) * 2006-10-31 2012-01-15 Surmodics Pharmaceuticals Inc Kugelförmige polymer-partikel
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) * 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
WO2009140246A2 (en) 2008-05-12 2009-11-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
CA2764063C (en) 2009-06-03 2019-05-14 Forsight Labs, Llc Anterior segment drug delivery
KR20180117211A (ko) * 2010-01-22 2018-10-26 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
US20130071349A1 (en) * 2010-03-02 2013-03-21 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
CN103313702A (zh) * 2010-06-30 2013-09-18 赢创有限公司 用于热不稳定及其它的生物活性剂的植入物的制备方法和由该方法制备的植入物
US9370444B2 (en) 2010-10-12 2016-06-21 Emmett T. Cunningham, JR. Subconjunctival conformer device and uses thereof
US8915877B2 (en) 2010-10-12 2014-12-23 Emmett T. Cunningham, JR. Glaucoma drainage device and uses thereof
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
EP3967297A1 (en) 2011-04-29 2022-03-16 Allergan, Inc. Sustained release latanoprost implant
CN106073986B (zh) 2011-09-14 2019-01-11 弗赛特影像5股份有限公司 治疗患者的眼睛的装置
US20140271772A1 (en) * 2013-03-15 2014-09-18 Barry J. Margulies Biodegradable subcutaneous implants and methods of making
BR122019025507B1 (pt) 2013-03-15 2021-01-12 Allergan, Inc. implante intraocular biodegradável contendo prostamida e seu uso
EP2978406A1 (en) * 2013-03-27 2016-02-03 Forsight Vision5, Inc. Bimatoprost ocular silicone inserts and methods of use thereof
EP3669865A1 (en) 2013-10-31 2020-06-24 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
MX2016007345A (es) * 2013-12-06 2016-12-09 Envisia Therapeutics Inc Implante intracameral para el tratamiento de una condicion ocular.
JP6550393B2 (ja) 2014-02-26 2019-07-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 眼内インプラント送出装置及び使用方法
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
WO2018064648A1 (en) * 2016-09-30 2018-04-05 Mati Therapeutics Inc. Ophthalmic drug sustained release formulation and uses thereof
US11911476B2 (en) * 2017-07-25 2024-02-27 Pk Med Process for preparing a drug delivery composition
KR102531760B1 (ko) * 2017-11-13 2023-05-10 한동희 다기능성 생체적합실
BR112021026265A2 (pt) 2019-06-27 2022-06-14 Layerbio Inc Métodos e sistemas de entrega de dispositivos oculares
CN114340598A (zh) * 2019-09-19 2022-04-12 Amw公司 用于受控制的有效成分释放的挤出式储库剂型
AU2021215929A1 (en) 2020-02-06 2022-08-04 Ocular Therapeutix, Inc. Compositions and methods for treating ocular diseases
IL312940A (en) * 2021-12-06 2024-07-01 Ocular Therapeutix Inc Eye supplements or implants and their methods
DE202024103267U1 (de) 2024-06-18 2024-07-09 Ashutosh Aggarwal Ein System zur Herstellung einer antihypertensiven Formulierung mit verlängerter Freisetzung

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126435U (ja) * 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Ｔｔｌオ−トストロボ用絞り制御回路
US4521210A (en) * 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
MY113268A (en) 1992-12-29 2002-01-31 Insite Vision Incorporated Plasticized bioerodible controlled delivery system
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5882327A (en) * 1997-04-17 1999-03-16 Jacob; Jean T. Long-term glaucoma drainage implant
CA2300154C (en) * 1997-08-11 2008-07-08 Allergan Sales, Inc. Sterile bioerodible implant device with improved biocompatability and method
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6743446B2 (en) 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
US20040175410A1 (en) * 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
AU3649502A (en) * 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
EP1387671A1 (en) * 2001-05-03 2004-02-11 MASSACHUSETTS EYE & EAR INFIRMARY Implantable drug delivery device and use thereof
AU2003295409B2 (en) * 2002-11-06 2010-02-11 Durect Corporation Controlled release depot formulations
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
WO2006031658A2 (en) 2004-09-10 2006-03-23 Allergan, Inc. Therapeutic lacrimal canalicular inserts and related methods
AU2005294382A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
WO2006080381A1 (ja) * 2005-01-28 2006-08-03 Terumo Kabushiki Kaisha 血管内インプラント
US9039761B2 (en) * 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) * 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US9504653B2 (en) * 2013-04-01 2016-11-29 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
EP3669865A1 (en) * 2013-10-31 2020-06-24 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof

Also Published As

Publication number Publication date
CA2673294C (en) 2015-07-21
PL2712610T3 (pl) 2018-05-30
EP3308769A1 (en) 2018-04-18
ES2851748T3 (es) 2021-09-08
US9149428B2 (en) 2015-10-06
US8846073B2 (en) 2014-09-30
DK3308769T3 (da) 2021-02-01
ES2657143T3 (es) 2018-03-01
CA2673294A1 (en) 2008-07-03
US10441543B2 (en) 2019-10-15
WO2008079674A3 (en) 2008-10-23
EP2712610A1 (en) 2014-04-02
JP2010513555A (ja) 2010-04-30
JP5484911B2 (ja) 2014-05-07
DK2712610T3 (da) 2018-01-29
PL3308769T3 (pl) 2021-07-26
US20160022581A1 (en) 2016-01-28
EP2124879B1 (en) 2016-05-25
EP2712610B1 (en) 2017-10-25
JP2014088448A (ja) 2014-05-15
US20200038326A1 (en) 2020-02-06
HUE030404T2 (en) 2017-05-29
AU2007337139A1 (en) 2008-07-03
HUE037939T2 (hu) 2018-09-28
EP3308769B1 (en) 2020-10-28
HK1253728A1 (zh) 2019-06-28
US20210322318A1 (en) 2021-10-21
JP5826872B2 (ja) 2015-12-02
US20080145403A1 (en) 2008-06-19
HUE053530T2 (hu) 2021-07-28
ES2588187T3 (es) 2016-10-31
EP2124879A2 (en) 2009-12-02
US20140364494A1 (en) 2014-12-11
WO2008079674A2 (en) 2008-07-03
DK2124879T3 (en) 2016-09-05
AU2007337139B2 (en) 2013-05-09

Similar Documents

Publication Publication Date Title
HK1253728A1 (zh) 製備用於眼內的環狀脂質植入物的方法
EP2485686B8 (en) Tibial implant base
GB0609911D0 (en) Bend-capable stent prosthesis
GB0607544D0 (en) Knee prothesis
EP2389140B8 (en) Knee prosthesis
PT2101676E (pt) Disposição para a inserção de implantes
EP1972306A4 (en) INSTRUMENT FOR INSERTING INTRAOCULAR LENSES
GB2484042B (en) Methods for manufacturing a patient-adapted tibial implant
IL227745A0 (en) Methods for manufacturing components for dental implants
GB201101112D0 (en) Prosthesis comprising an artificial ligament
EP1983936A4 (en) RETINAL PROSTHESIS AT LARGE FIELD
EP2020960A4 (en) INTRAOCULAR CAMERA FOR NETWORK SKIN PROTESTS
HK1137640A1 (en) Intraocular lens inserting instrument
EP2001427A4 (en) INTRAOCULAR IMPLANT
IL192559A0 (en) Hybrid stent
IL198765A0 (en) Supraosseous dental implant
EP2059194A4 (en) WRIST IMPLANTS
EP2049713A4 (en) TISSUE REJECTION
EP2081520A4 (en) MEDICAL IMPLANTS
EP2005880A4 (en) OPHTHALMOLOGICAL INSTRUMENT
GB2443163B (en) Shoulder prosthesis
GB0707418D0 (en) Dental implants
GB0612242D0 (en) Retinal prosthetic devices
GB0608345D0 (en) Implant
GB0618930D0 (en) Medical implant